Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Poliomyelitis|Diphtheria|Hepatitis B|Tetanus|Influenza, Human
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01106092 |
NCT01106092 | P2 |
Completed |
Hepatitis B|Influenza, Human|Tetanus|Diphtheria|Poliomyelitis |
2010-09-02 |
2019-10-02 |
Primary Endpoints|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|